

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 1993

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OR THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission file number 1-9114

MYLAN LABORATORIES INC.

(Exact Name of registrant as specified in its charter)

Pennsylvania 25-1211621
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

130 Seventh Street
1030 Century Building
Pittsburgh, Pennsylvania 15222
(Address of principal executive offices) (Zip Code)

412-232-0100
(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed
since last report)

Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding twelve
months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:

YES X NO

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date

Class of Common Stock	Outstanding at January 21, 1994
\$.50 par value	79,149,950

MYLAN LABORATORIES INC. AND SUBSIDIARIES

INDEX

Page
Number

PART I. FINANCIAL INFORMATION

Consolidated Balance Sheets - December 31, 1993
and March 31, 1993

2A and 2B

Consolidated Statements of Earnings - Three and Nine Months Ended December 31, 1993 and 1992	3
Consolidated Statements of Cash Flows - Nine Months Ended December 31, 1993 and 1992	4
Notes to Consolidated Financial Statements - Three and Nine Months Ended December 31, 1993	5, 6 and 7
Management's Discussion and Analysis of Financial Condition and Results of Operations	8 and 9
PART II. OTHER INFORMATION	10

MYLAN LABORATORIES INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
ASSETS

	December 31, 1993 Unaudited	March 31, 1993 Audited
Current Assets		
Cash and cash equivalents	\$103,021,000	\$ 98,246,000
Accounts receivable	48,774,000	32,396,000
Inventories:		
Raw materials	25,316,000	23,115,000
Work in process	12,153,000	11,553,000
Finished goods	17,262,000	11,281,000
Deferred tax benefit		
Other current assets	1,284,000	-
	7,090,000	3,891,000
Total Current Assets	214,900,000	180,482,000
Property, Plant and Equipment - at cost	106,160,000	94,950,000
Less accumulated depreciation	30,929,000	26,431,000
	75,231,000	68,519,000
Investment in and Advances to Somerset	17,827,000	14,844,000
Intangible Assets net of accumulated amortization	34,448,000	38,115,000
Other Assets	51,240,000	49,145,000
Total Assets	\$393,646,000	\$351,105,000

See Notes to Consolidated Financial Statements

-2A-

LIABILITIES AND SHAREHOLDERS' EQUITY

[CAPTION]

	December 31, 1993 Unaudited	March 31, 1993 Audited
Current Liabilities		
Trade accounts payable	\$ 5,686,000	\$ 6,492,000
Income taxes payable	2,242,000	9,349,000
Other current liabilities	12,783,000	8,293,000
Cash dividend payable	3,168,000	2,348,000
Total Current Liabilities	23,879,000	26,482,000
Acquisition Obligation	-	21,303,000
Long-Term Obligations	4,363,000	5,125,000
Deferred Income Taxes	271,000	2,223,000
Shareholders' Equity:		
Preferred stock, par value \$.50 per share, authorized 5,000,000 shares, issued and outstanding - none	-	-
Common stock, par value \$.50 per share, authorized 300,000,000 shares, issued 79,624,339 shares at December 31, 1993		
78,615,453 shares at March 31, 1993	39,812,000	39,309,000
Additional paid in capital	53,699,000	29,866,000
Retained earnings	274,131,000	227,139,000
	367,642,000	296,314,000
Less Treasury stock - at cost, 495,864 shares at December 31, 1993 and 430,206 shares at March 31, 1993	2,509,000	342,000
Net Worth	365,133,000	295,972,000
Total Liabilities and Shareholders' Equity	\$393,646,000	\$351,105,000

See Notes to Consolidated Financial Statements

-2B-

MYLAN LABORATORIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
UNAUDITED

	Three Months Ended December 31, 1993	1992	Nine Months Ended December 31, 1993	1992
NET SALES	\$ 66,436,000	\$ 61,108,000	<C >	\$182,699,000
COST AND EXPENSES:				
Cost of Sales	32,165,000	24,489,000	90,628,000	64,920,000
Research and Development	5,499,000	3,804,000	16,453,000	10,123,000
Selling and Administrative	14,284,000	10,681,000	36,745,000	26,920,000
Interest Expense	8,000	8,000	23,000	26,000
EQUITY IN EARNINGS OF SOMERSET	51,956,000	38,982,000	143,849,000	101,989,000
OTHER INCOME	6,841,000	6,120,000	18,250,000	15,530,000
EARNINGS BEFORE INCOME TAXES	4,634,000	1,423,000	7,481,000	2,479,000
INCOME TAX RATE	25,955,000	29,669,000	64,581,000	66,986,000
	15%	29%	14%	26%

INCOME TAXES	3,832,000	8,494,000	8,908,000	17,751,000
NET EARNINGS	\$ 22,123,000	\$ 21,175,000	\$ 55,673,000	\$ 49,235,000
EARNINGS PER SHARE	\$.28	\$.28	\$.71	\$.64
WEIGHTED AVERAGE COMMON SHARES	79,091,000	76,974,000	78,876,000	76,902,000

The Company paid regular quarterly cash dividends of \$.025 per share from July 1990 to July 1992, \$.03 per share from October 1992 to July 1993 and \$.04 per share on October 15, 1993 and January 15, 1994.

See Notes to Consolidated Financial Statements

-3-

MYLAN LABORATORIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED DECEMBER 31, 1993 AND 1992

UNAUDITED

[CAPTION]

	1993	1992
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Earnings	\$ 55,673,000	\$ 49,235,000
Adjustments to reconcile net earnings to net cash from operating activities:		
Depreciation and amortization	8,232,000	3,713,000
Deferred income taxes	(434,000)	(100,000)
Equity in the earnings of Somerset	(18,250,000)	(15,530,000)
Cash received from Somerset	15,267,000	13,988,000
Other non-cash expenses	8,113,000	5,887,000
Changes in operating assets and liabilities:		
Accounts receivable	(21,064,000)	(11,091,000)
Inventories	(8,737,000)	(7,811,000)
Trade accounts payable	(806,000)	(27,000)
Income taxes payable	(8,869,000)	2,560,000
Other operating assets and liabilities	(3,869,000)	3,726,000
NET cash provided from operating activities	25,256,000	44,550,000
CASH FLOWS FROM INVESTING ACTIVITIES		
Additions to property, plant and equipment	(11,210,000)	(7,509,000)
Increase in other assets	(1,214,000)	(10,977,000)
Net cash used in investing activities	(12,424,000)	(18,486,000)
CASH FLOWS FROM FINANCING ACTIVITIES		
Cash dividend paid	(7,861,000)	(6,152,000)
Payments on long-term debt	(14,000)	(50,000)
Payments on acquisition obligations	(977,000)	-
Proceeds from exercise of stock options	795,000	9,208,000
Net cash provided from (used in) financing activities	(8,057,000)	3,006,000
Net Increase in Cash and Cash Equivalents	4,775,000	29,070,000
Cash and Cash Equivalents - Beginning of Period	98,246,000	60,324,000
Cash and Cash Equivalents - End of Period	\$103,021,000	\$ 89,394,000
CASH PAID DURING THE PERIOD FOR:		
Interest	\$ 23,000	\$ 23,000
Income Taxes	\$ 11,417,000	\$ 15,234,000

See Notes to Consolidated Financial Statements

-4-

MYLAN LABORATORIES INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
THREE AND NINE MONTH PERIOD ENDED
DECEMBER 31, 1993

Unaudited

- A. On November 5, 1993 Roy McKnight, Chairman and Chief Executive Officer of the Company since 1976, suffered a fatal heart attack. Mr. McKnight passed away the following day. On November 9, 1993 Milan Puskar was named Chairman and C.E.O. in addition to his existing position as President of the Company. Also, C.B. Todd, President of the Company's wholly owned subsidiary Mylan Pharmaceuticals Inc., was appointed to the Board of Directors of the Company. The Company has certain obligations to the estate and/or family of Mr. McKnight pursuant to a 1990 salary continuation agreement. A one time charge against earnings of approximately \$2.8 million is included in Selling and Administrative expenses in the quarter ended December 31, 1993 relating to these obligations. At December 31, 1993 other accrued liabilities includes a total of \$4,306,000 which has been accrued by the Company for this obligation.
- B. On November 24, 1993 the Company reached a settlement with Pharmaceuticals Resources, Inc./Par Pharmaceuticals/Quad Pharmaceuticals, three defendants in the Company's suit filed under the Federal Antitrust Laws and the Racketeer Influenced and Corrupt Organization Act (RICO), against several pharmaceutical companies, certain employees of those Companies and certain former employees of the FDA Generic Drug Division. Under the settlement, Pharmaceutical Resources, Inc. agreed to pay the Company the sum of \$1,000,000 in cash and \$2,000,000 in their common stock. This settlement is reflected under the caption "Other Income" for the quarter ended December 31, 1993.
- C. On February 25, 1993, a wholly owned subsidiary of the Company acquired substantially all of the net assets of Bertek Inc. (Bertek) for approximately \$39,112,000 and assumed liabilities of approximately \$10,090,000. The business combination has been accounted for under the purchase method of accounting. Goodwill of approximately \$2,686,000 resulting from the acquisition is being amortized on a straight-line basis over a 20 year period. To facilitate the transaction the Company issued 1,349,975 shares of its common stock and paid cash of \$9,375,000 including approximately \$8,293,000 paid by the Company at closing to satisfy certain long-term obligations assumed.

-5-

MYLAN LABORATORIES INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

- D. Effective April 1, 1993 the Company adopted Statement of Financial Accounting Standards (SFAS) No. 109 "Accounting for Income Taxes". Prior years financial statements were not restated. The cumulative effect of adopting this standard resulted in an increase in net earnings of \$1,124,000 (\$.01 per share) for the three months ended June 30, 1993. There was no cash flow impact. Expanded disclosure regarding the impact of the adoption of SFAS 109 was provided in the Report on Form 10-Q for the quarter ended June 30, 1993.

SFAS 109 requires an asset and liability approach to accounting for income taxes. Deferred tax assets and liabilities reflect the future tax consequences of events that have already been recognized in the financial statements or tax returns. Changes in enacted tax rates or laws will result in adjustments to the recorded tax asset or liabilities in the period that the tax law is enacted.

In August of 1993, President Clinton signed into law the

Omnibus Budget Reconciliation Act of 1993 ("the Act"). The Act has several provisions which effect the Company's income tax expense including a change in the Federal corporate tax rate and significant changes relating to tax credits for operations in Puerto Rico. As a direct result of the changes in the tax code, the Company reassessed its position on the filing alternatives available under the tax code. Based on the new tax code provisions, the Company made a decision which resulted in a reduction of income tax expense of \$3,225,000. This amount represents management's estimate of the cumulative effect of this change.

E. In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of December 31, 1993 and March 31, 1993 together with the results of operations and cash flows for the interim periods ended December 31, 1993 and 1992. The consolidated results of operations for the three and nine months ended December 31, 1993 and 1992 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto in the Company's 1993 Annual Report.

-6-

MYLAN LABORATORIES INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

F. Equity in Earnings of Somerset includes the Company's 50% portion of the net earnings of Somerset Pharmaceuticals Inc. (Somerset), certain management fees and amortization of intangible assets resulting from the acquisition of Somerset. Such intangible assets are being amortized over a 15 year period using the straight line method.

Condensed unaudited financial information of Somerset for the three and nine month periods ended December 31, 1993 and 1992 are as follows: (in thousands)

	Three Months Ended December 31,		Nine Months Ended December 31,	
	1993	1992	1993	1992
Net Sales	\$36,422	\$32,538	\$88,107	\$77,628
Costs and Expenses	(19,470)	(15,687)	(40,789)	(34,840)
Income Taxes	(5,070)	(6,236)	(15,220)	(15,601)
Net Earnings	\$11,882	\$10,615	\$32,098	\$27,187

The above information represents 100% of Somerset's operations of which the Company has a 50% interest.

PART 1 - FINANCIAL INFORMATION

ITEM 2 - MANagements DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

Net sales for the three months ended December 31, 1993 were a record high \$66,436,000 exceeding the previous record high quarterly sales for the same quarter a year ago by 9%. For the nine month period ended December 31, 1993 net sales were \$182,699,000 representing a 21% increase over the same period a year ago. Sales of five new generic products added to the Company's product line in December and an overall increase in generic volume, up 15% quarter to quarter and 25% year to date, along with sales revenues from Bertek which was acquired in February 1993, have helped to offset significant price erosion which continues to effect products added to the generic line during the last fiscal year.

As a direct result of significant pricing competition in the generic markets and the addition of Bertek revenues, which generally provide lower gross margin rates, gross margin as a percent of sales has decreased from 60% for the December 1992 quarter to 52% this year and from 57% for the nine months ended December 1992 to 50% this year.

Indicative of the Company's commitment to new and increased product development to broaden the Company's product line, current year expenditures for research and development have increased significantly over prior years. This increase is due to research projects throughout the Company.

As discussed in footnote A, Selling and Administrative expenses for the quarter ended December 31, 1993 includes a charge of \$2,800,000 for obligations pursuant to a salary continuation agreement for Mr. McKnight. Excluding this one time charge, Selling and Administrative expenses were 17% of net sales for the quarters ended December 31, 1993 and 1992 and were 19% of sales for the nine month period ended December 31, 1993 versus 18% last year. Amortization of intangible assets associated with the Bertek acquisition of approximately \$3,000,000 are included in the 1993 year to date amount. Other factors contributing to the increase include advertising and promotion expenses associated with new products and legal and professional fees associated with the various court actions to which the Company is a party.

Equity in earnings of Somerset continues to provide a solid return for the Company. Somerset's contribution to net earnings per share for the three and nine month periods was \$.08 and \$.21 in 1993 and \$.07 and \$.18 in 1992.

Effective April 1, 1993 the Company adopted Statement of Financial Accounting Standards (SFAS) No. 109 "Accounting for Income Taxes" which resulted in a reduction of income tax expense and a corresponding increase in net earnings during the quarter ended June 30, 1993 of \$1,124,000 or \$.01 per share.

During the quarter ended September 30, 1993, as a direct result of changes in the Federal Tax Code enacted in August of 1993, the

Company reassessed its position on the filing alternatives available under the tax code. Based on the new tax code provision the Company made a decision which resulted in a reduction of income tax expense of \$3,225,000. Excluding the effects of adoption of FAS 109 and the management decision predicated on the changes in the tax code, the effective tax rate for the nine months ended December 31, 1993 is roughly 21% compared to 25% for the same period a year ago. This decrease is due to higher levels of production at the Company's Puerto Rico facility.

Liquidity and Capital Resources and Financial Condition

Working capital increased from \$154,000,000 at March 31, 1993 to \$191,021,000 at December 31, 1993 as a result of continued strong operations. The ratio of current assets to current liabilities was 6.8 to 1 at March 31, 1993 and 9.0 to 1 at December 31, 1993.

Cash flows from operating activities remain strong but have decreased from the prior year due principally to the timing of new product sales and increased levels of operating expenditures and inventory purchases.

Additions to property, plant and equipment amounted to \$11,210,000 in the current year including construction projects at the Company's West Virginia and Puerto Rico facilities and new projects at the Bertek facility in Vermont.

-9-

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On November 24, 1993 the Company reached a settlement with Pharmaceuticals Resources, Inc./Par Pharmaceuticals/Quad Pharmaceuticals, three defendants in the Company's suit filed under the Federal Antitrust Laws and the Racketeer Influenced and Corrupt Organization Act (RICO), against several pharmaceutical companies, certain employees of those Companies and certain former employees of the FDA Generic Drug Division. Under the settlement, Pharmaceutical Resources, Inc. agreed to pay the Company the sum of \$1,000,000 in cash and \$2,000,000 in their common stock.

Item 6. Exhibits and Reports on Form 8-K

(b) Reports on Form 8-K - On November 15, 1993 the Company filed a report on Form 8-K dated November 6, 1993 covering Item 5 thereof regarding the death of Roy McKnight and the appointments of Milan Puskar as Chairman and Chief Executive Officer and C.B. Todd as a member of the board of directors.

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of
The Securities Act of 1934

Date of Report (Date of earliest event reported) November 6, 1993

MYLAN LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-9114	25-1211621
(State or other	(Commission	(I.R.S. Employer
jurisdiction of	File Number)	Identification No.)
incorporation)		

130 Seventh Street
1030 Century Building
Pittsburgh, PA 15222
(Address of principal executive offices)

Registrant's telephone number, including area code (412) 232-0100

Item 5. Other Events.

On November 9, 1993, the board of directors of Mylan Laboratories Inc. (the "Registrant") named Milan Puskar, age 59, as its Chairman and Chief Executive Officer, in addition to his current position as President, and named C.B. Todd as a member of its board of directors. Mr. Puskar succeeds Roy McKnight, who was stricken by a fatal heart attack the previous weekend, and Mr. Todd's election fills the resulting vacancy on the board. Mr. Todd, age 59, is a Senior Vice President of the Registrant, a member of its Executive Committee and President of Mylan Pharmaceuticals, Inc., a wholly-owned subsidiary of the Registrant. He has served in various positions with the Registrant since 1970.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN LABORATORIES INC.

By: /S/ Milan Puskar
Milan Puskar, Chairman,
Chief Executive Officer and
President

Date: November 12, 1993
Pittsburgh, Pennsylvania

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Mylan Laboratories Inc.
(Registrant)

DATE /S/ Milan Puskar 2/3/94
Milan Puskar
Chairman, President & C.E.O.

DATE /S/ Frank A. DeGeorge 2/3/94
Frank A. DeGeorge
Director of Accounting and Taxation